January 2012 in “Hacettepe University Institutional Repository (hacettepe.edu.tr)” Microbeam Radiation Therapy is effective, but using a linear accelerator reduces its benefits.
1 citations
,
April 1953 in “Acta Radiologica” Irradiating the whole central nervous system can lead to over 50% of patients with cerebellar medulloblastoma surviving three years.
May 2016 in “International Society of Hair Restoration Surgery” Careful planning and technique are crucial for successful hair transplants on irradiated scalps.
19 citations
,
October 2009 in “Bioorganic & Medicinal Chemistry Letters” Thyroid receptor agonists may treat male pattern baldness without harmful side effects.
1 citations
,
July 2016 in “Dermatologic surgery”
February 2024 in “Folia Medica” Platelet-rich plasma treatment is effective for hair loss in patients regardless of their thyroid antibody levels.
3 citations
,
September 2024 in “Dermatology and Therapy” Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
November 2022 in “Journal of the Endocrine Society” Excessive iodine from a cystic fibrosis supplement can cause hypothyroidism.
8 citations
,
March 1942 in “Journal of Endocrinology” Thyroid hormone treatments help thyroidectomized rats grow normally.
Hair transplant is effective for treating hair loss caused by radiation and improves patients' quality of life.
January 2017 in “프로그램북(구 초록집)” 7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
4 citations
,
October 2024 in “American Journal of Clinical Dermatology” Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
2 citations
,
January 1992 in “Neurologia medico-chirurgica” The new therapy effectively targets brain tumors while minimizing damage to healthy tissue.
The treatment was not recommended due to limited effectiveness and significant side effects.
January 2026 in “International Journal of Dermatology” Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.
5 citations
,
May 2006 in “Dermatologic Surgery” Radiation therapy successfully treated an elderly man's skin cancer and pre-cancerous scalp lesions.
May 2006 in “Dermatologic Surgery” Radiation therapy successfully treated an elderly man's skin cancer and pre-cancerous scalp lesions.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
October 2025 in “Dermatology and Therapy”
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Thorough evaluation and treatment are crucial for thyroid nodules.
5 citations
,
January 2004 in “Biochimie” Arsenic trioxide effectively treats APL, improving survival rates despite its toxicity.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
27 citations
,
January 2018 in “Drug Delivery” GC10/DOX hydrogel shows promise as an effective thyroid cancer treatment.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.